Last deal

$20.6M

Amount

Series B

Stage

28.09.2020

Date

2

all rounds

$37.6M

Total amount

date founded

Financing round

General

About Company
ILIAS Biologics develops exosome-based therapeutics for hard-to-treat inflammatory and metabolic diseases.

Industry

Sector :

Subsector :

Keywords :

Also Known As

일리아스바이오로직스

founded date

02.11.2015

founders

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

The company's proprietary platform technology, EXPLOR®, enables medical professionals to load large therapeutic molecules into exosomes, which are extracellular vesicles naturally released by cells. ILIAS Biologics is dedicated to developing engineered exosomes that can deliver therapeutic proteins to intracellular pathways to treat life-threatening and rare diseases. The company is expanding its global network of research and business alliances to maximize the potential of its novel exosome platform technology.
Similar Companies
999
Inhibrx

Inhibrx

Inhibrx is a biotech company focused on developing optimized biologic therapeutics for life-threatening conditions.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

La Jolla, San Diego, CA, USA

total rounds

5

total raised

$269.59M
ProThera Biologics

ProThera Biologics

ProThera Biologics develops bio-therapeutics for treating inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

East Providence, RI, USA

total rounds

1

total raised

$750K
Siolta Therapeutics

Siolta Therapeutics

Siolta Therapeutics is a biotech company that develops microbial therapeutics to prevent and treat inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Carlos, CA, USA

total rounds

5

total raised

$42M
Tentarix Biotherapeutics

Tentarix Biotherapeutics

Tentarix creates innovative protein therapeutics using synthetic biology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

La Jolla, San Diego, CA, USA

total rounds

4

total raised

$93M

Financials

Funding Rounds
2
2

Number of Funding Rounds

$37.6M

Money Raised

Their latest funding was raised on 28.09.2020. Their latest investor Kiwoom Investment. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
28.09.2020
10
$20.6M
01.05.2018
$17M
Co-Investors
Investors
10
0

Number of lead investors

10

Number of investors

Investor 
Lead 
Round 
Partners 
Kiwoom Investment

Kiwoom Investment

The represented VC is a South Korean company that provides financial assistance to small businesses.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Location

Seoul, South Korea

count Of Investments

60
Daedeok Venture Partners

Daedeok Venture Partners

Daedeok Venture Partners is a technology-focused VC firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Daejeon, Jeong-dong, Daejeon, South Korea

count Of Investments

34
Daishin Securities

Daishin Securities

Daishin Securities is a financial investment company that aims to improve people's lifestyles through communication and balance.

Sector

Investment Banking and Brokerage Services

Subsector

Investment Services

Location

Seoul, South Korea

count Of Investments

16

count Of Exists

1

People

Founders
1
Chulhee Choi
Chulhee Choi

Chulhee Choi

Chulhee Choi is the Chief Executive Officer and the Founder of ILIAS Biologics.

current job

ILIAS Biologics
ILIAS Biologics

organization founded

1

Chulhee Choi

Employee Profiles
4
Chulhee Choi

Chulhee Choi

Founder and CEO

Jun Tae Park

Jun Tae Park

EVP and Chief Scientific Officer

Taejin Ham

Taejin Ham

EVP and Chief Operating Officer

Sangchul Kim

Sangchul Kim

Executive Vice President

Activity

Recent News
0